Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects

Molecular pharmacogenetic units have recently been established in several hospital laboratories in France. The clinical impact of these units is still limited and numerous problems of organizational, ethical, legal, technical, social and economical nature remain to be resolved. However, an increasin...

Full description

Saved in:
Bibliographic Details
Published inAnnales pharmaceutiques françaises Vol. 65; no. 6; p. 371
Main Authors Allorge, D, Beaune, P-H, Becquemont, L, Bessard, G, Bezieau, S, Boisdron-Celle, M, Boyer, J-C, Broly, F, Dhaneens, C-M, Fonrose, X, Gagnieu, M-C, Gamelin, E, Gozé, C, Jacqz-Aigrain, E, Loric, S, Loriot, M-A, Marquet, P, Morel, A, Namour, B, Paintaud, G, Peoc'h, K, Picard, N, Watier, H, Verstuyft, C
Format Journal Article
LanguageFrench
Published France 01.11.2007
Subjects
Drug-Related Side Effects and Adverse Reactions
France
Humans
Laboratories, Hospital - ethics
Laboratories, Hospital - statistics & numerical data
Laboratories, Hospital - trends
Methyltransferases - deficiency
Methyltransferases - genetics
Pharmacogenetics - ethics
Pharmacogenetics - statistics & numerical data
Pharmacogenetics - trends
Public Health
France
Online AccessGet more information

Cover

More Information
Summary:Molecular pharmacogenetic units have recently been established in several hospital laboratories in France. The clinical impact of these units is still limited and numerous problems of organizational, ethical, legal, technical, social and economical nature remain to be resolved. However, an increasing number of these units, a rise in their activities and an enlargement of their scope of application are foreseeable in the future. Ultimately, these units would significantly contribute to limit the public health problem caused by interindividual variabilities in drug effects. In view of these prospects, it seems essential that such hospital activity should be quickly recognised by the authorities and the various health sectors in France. It is also essential that the problems that arise from such pharmacogenetic activities should be considered by the authorities and would profit from the organization of a national network and from financial guarantees.
ISSN:0003-4509